1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-78. PMID:
11857671
2. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543-62. PMID:
18599186
3. Brostrom S, Hallas J. Persistence of antimuscarinic drug use. Eur J Clin Pharmacol 2009;65:309-14. PMID:
19107469
4. Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 2012;188(6 Suppl):2455-63. PMID:
23098785
5. Allahdin S, Oo N. An overview of treatment of overactive bladder syndrome in women. J Obstet Gynaecol 2012;32:217-21. PMID:
22369391
6. Balchandra P, Rogerson L. Women’s perspective: intra-detrusor botox versus sacral neuromodulation for overactive bladder symptoms after unsuccessful anticholinergic treatment. Int Urogynecol J 2014;25:1059-64. PMID:
24633067
7. Sahai A, Dowson C, Khan MS, Dasgupta P. Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. BJU Int 2009;103:1509-15. PMID:
19389019
8. Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P. Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn 2011;30:556-62. PMID:
21351127
9. Tincello DG, Kenyon S, Abrams KR, Mayne C, Toozs-Hobson P, Taylor D, et al. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol 2012;62:507-14. PMID:
22236796
10. Denys P, Le Normand L, Ghout I, Costa P, Chartier-Kastler E, Grise P, et al. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study. Eur Urol 2012;61:520-9. PMID:
22036776
11. Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007;177:2231-6. PMID:
17509328
12. Reitz A, Denys P, Fermanian C, Schurch B, Comperat E, Chartier-Kastler E. Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur Urol 2007;52:1729-35. PMID:
17884281
13. Sahai A, Dowson C, Khan MS, Dasgupta P; GKT Botulinum Study Group. Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity. Urology 2010;75:552-8. PMID:
20035984
14. Abeywickrama L, Arunkalaivanan A, Quinlan M. Repeated botulinum toxin type A (Dysport) injections for women with intractable detrusor overactivity: a prospective outcome study. Int Urogynecol J 2014;25:601-5. PMID:
24132493
15. Dowson C, Watkins J, Khan MS, Dasgupta P, Sahai A. Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur Urol 2012;61:834-9. PMID:
22204745
16. Veeratterapillay R, Harding C, Teo L, Vasdev N, Abroaf A, Dorkin TJ, et al. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin typeA injections for detrusor overactivity. Int J Urol 2014;21:175-8. PMID:
23819724
17. The American College of Obstetricians and Gynecologists. OnabotulinumtoxinA and the bladder. Committee Opinion No. 604. Obstet Gynecol 2014;123:1408-11. PMID:
24848923
18. Apostolidis A, Dasgupta P, Denys P, Elneil S, Fowler CJ, Giannantoni A, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 2009;55:100-19. PMID:
18823697
19. White WM, Pickens RB, Doggweiler R, Klein FA. Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population. J Urol 2008;180:2522-6. PMID:
18930481
20. Brierly RD, Hindley RG, McLarty E, Harding DM, Thomas PJ. A prospective evaluation of detrusor ultrastructural changes in bladder outlet obstruction. BJU Int 2003;91:360-4. PMID:
12603415
21. Mirone V, Imbimbo C, Longo N, Fusco F. The detrusor muscle: an innocent victim of bladder outlet obstruction. Eur Urol 2007;51:57-66. PMID:
16979287
22. Gosling JA. Modification of bladder structure in response to out-flow obstruction and ageing. Eur Urol 1997;32 Suppl 1:9-14. PMID:
9218937
23. Liao LM, Schaefer W. Cross-sectional and longitudinal studies on interaction between bladder compliance and outflow obstruction in men with benign prostatic hyperplasia. Asian J Androl 2007;9:51-6. PMID:
16888684
24. Madersbacher S, Pycha A, Klingler CH, Mian C, Djavan B, Stulnig T, et al. Interrelationships of bladder compliance with age, detrusor instability, and obstruction in elderly men with lower urinary tract symptoms. Neurourol Urodyn 1999;18:3-15. PMID:
10090122
25. Habashy D, Losco G, Tse V, Collins R, Chan L. Botulinum toxin (OnabotulinumtoxinA) in the male non-neurogenic overactive bladder: clinical and quality of life outcomes. BJU Int 2015;116 Suppl 3:61-5. PMID:
26176660
26. Mohee A, Khan A, Harris N, Eardley I. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int 2013;111:106-13. PMID:
22672569